Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Castle Biosciences Incorporated
- Study ID
- NCT07645820
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - 89 Years
- Healthy Volunteers
- Not accepted
Interventions
- Nevisense electrical impedance spectroscopy — DEVICEThe NevisenseGo device will collect skin measurements from people with atopic dermatitis (AD) to see if it can effectively predict a flare in disease.
Study Details
This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device. Participants aged 12 to 89 years with a history of AD flares will use the device at home for about 90 days. Participants will complete device measurements, electronic diary entries, and up to five in-person study visits. The study is based on the idea that changes in skin barrier function may occur before an AD flare becomes visible or symptoms begin. Information collected during the study, including device measurements, diary entries, and investigator assessments, will be used to evaluate whether these changes may help estimate the likelihood of an AD flare before visible signs or symptoms occur.
Key Dates
- Start date
- May 29, 2026
- Status verified
- Jun 2026
- Primary completion
- Apr 1, 2027
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 450 participants (estimated)
Primary Outcome Measure
Relationship between skin measurements and subsequent atopic dermatitis flares [ Time Frame: Measurements taken over 90 days, 5 days a week ]
Central Contacts
- Clare Johnson E VP Clinical Research602-499-0301
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| U.S. Dermatology Partners | Phoenix | Arizona | 85006 | Margaret Kessler, MD (PRINCIPAL_INVESTIGATOR) |
| Las Vegas Dermatology | Las Vegas | Nevada | 89144 | David Cotter, MD, PhD (PRINCIPAL_INVESTIGATOR) |
| StracSkin, PLLC | Portsmouth | New Hampshire | 03801 | Abel Jarell, MD, FAAD (PRINCIPAL_INVESTIGATOR) |
| Harrison Institute for Clinical Research | Missouri City | Texas | 77459 | Harrison Nguyen, MD, MBA, MPH, DTM&H FAAD |
Find similar trials in Phoenix, AZ
Related Studies
- A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisPHASE3 · Enrolling By Invitation · Eli Lilly and Company · Birmingham, Alabama
- A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic DermatitisPHASE2 · Recruiting · Pfizer · Birmingham, Alabama
- A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to DupilumabPHASE3 · Recruiting · AbbVie · Birmingham, Alabama
- Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic DermatitisPHASE2 · Recruiting · Oneness Biotech Co., Ltd. · Fountain Valley, California